These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34942941)

  • 1. Neuropsychological Characterization of Aggressive Behavior in Children and Adolescents with CD/ODD and Effects of Single Doses of Medications: The Protocol of the Matrics_WP6-1 Study.
    Balia C; Carucci S; Milone A; Romaniello R; Valente E; Donno F; Montesanto A; Brovedani P; Masi G; Glennon JC; Coghill D; Zuddas A; The Matrics Consortium
    Brain Sci; 2021 Dec; 11(12):. PubMed ID: 34942941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):52-61. PubMed ID: 25886656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.
    Gorman DA; Gardner DM; Murphy AL; Feldman M; Bélanger SA; Steele MM; Boylan K; Cochrane-Brink K; Goldade R; Soper PR; Ustina J; Pringsheim T
    Can J Psychiatry; 2015 Feb; 60(2):62-76. PubMed ID: 25886657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Executive functioning and emotion recognition in youth with oppositional defiant disorder and/or conduct disorder.
    Kleine Deters R; Naaijen J; Rosa M; Aggensteiner PM; Banaschewski T; Saam MC; Schulze UME; Sethi A; Craig MC; Sagar-Ouriaghli I; Santosh P; Castro-Fornieles J; Penzol MJ; Arango C; Werhahn JE; Brandeis D; Franke B; Glennon J; Buitelaar JK; Hoekstra PJ; Dietrich A
    World J Biol Psychiatry; 2020 Sep; 21(7):539-551. PubMed ID: 32212964
    [No Abstract]   [Full Text] [Related]  

  • 7. Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
    Blader JC; Pliszka SR; Kafantaris V; Foley CA; Crowell JA; Carlson GA; Sauder CL; Margulies DM; Sinha C; Sverd J; Matthews TL; Bailey BY; Daviss WB
    J Am Acad Child Adolesc Psychiatry; 2013 Dec; 52(12):1281-93. PubMed ID: 24290461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emotional face recognition in male adolescents with autism spectrum disorder or disruptive behavior disorder: an eye-tracking study.
    Bours CCAH; Bakker-Huvenaars MJ; Tramper J; Bielczyk N; Scheepers F; Nijhof KS; Baanders AN; Lambregts-Rommelse NNJ; Medendorp P; Glennon JC; Buitelaar JK
    Eur Child Adolesc Psychiatry; 2018 Sep; 27(9):1143-1157. PubMed ID: 29922873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. START NOW - a comprehensive skills training programme for female adolescents with oppositional defiant and conduct disorders: study protocol for a cluster-randomised controlled trial.
    Kersten L; Prätzlich M; Mannstadt S; Ackermann K; Kohls G; Oldenhof H; Saure D; Krieger K; Herpertz-Dahlmann B; Popma A; Freitag CM; Trestman RL; Stadler C
    Trials; 2016 Dec; 17(1):568. PubMed ID: 27903282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential neuropsychological functioning between adolescents with attention-deficit/hyperactivity disorder with and without conduct disorder.
    Lin YJ; Gau SS
    J Formos Med Assoc; 2017 Dec; 116(12):946-955. PubMed ID: 28292624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Improvement in Externalizing Behaviors and Callous-Unemotional Traits in Children with Disruptive Behavior Disorder: A 1-Year Follow Up Clinic-Based Study.
    Muratori P; Milone A; Manfredi A; Polidori L; Ruglioni L; Lambruschi F; Masi G; Lochman JE
    Adm Policy Ment Health; 2017 Jul; 44(4):452-462. PubMed ID: 26008901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory Control Deficits in Children with Oppositional Defiant Disorder and Conduct Disorder Compared to Attention Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.
    Bonham MD; Shanley DC; Waters AM; Elvin OM
    Res Child Adolesc Psychopathol; 2021 Jan; 49(1):39-62. PubMed ID: 33048265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of anxiety in cortisol stress response and cortisol recovery in boys with oppositional defiant disorder/conduct disorder.
    Schoorl J; Rijn SV; Wied M; van Goozen S; Swaab H
    Psychoneuroendocrinology; 2016 Nov; 73():217-223. PubMed ID: 27521740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals.
    Bakker-Huvenaars MJ; Greven CU; Herpers P; Wiegers E; Jansen A; van der Steen R; van Herwaarden AE; Baanders AN; Nijhof KS; Scheepers F; Rommelse N; Glennon JC; Buitelaar JK
    Eur Neuropsychopharmacol; 2020 Jan; 30():87-101. PubMed ID: 30201120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying the Inter-Domain Relations Among ODD, CD, and CU Traits in Preschool Children Using Network Analysis.
    Bansal PS; Goh PK; Eng AG; Elkins AR; Thaxton M; Smith TE; Martel MM
    Res Child Adolesc Psychopathol; 2021 Oct; 49(10):1289-1301. PubMed ID: 34128173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability in emotional/behavioral problems in boys with oppositional defiant disorder or conduct disorder: the role of arousal.
    Schoorl J; Van Rijn S; De Wied M; Van Goozen SH; Swaab H
    Eur Child Adolesc Psychiatry; 2016 Aug; 25(8):821-30. PubMed ID: 26608403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of cool and hot executive function in ODD/CD independently of ADHD.
    Hobson CW; Scott S; Rubia K
    J Child Psychol Psychiatry; 2011 Oct; 52(10):1035-43. PubMed ID: 21827452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive Function Features in Drug-naive Children with Oppositional Defiant Disorder.
    Xu M; Jiang W; DU Y; Li Y; Fan J
    Shanghai Arch Psychiatry; 2017 Aug; 29(4):228-236. PubMed ID: 28955142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.